The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis
Open accessAbstract
OBJECTIVE: To analyse the available evidence on cardiovascular safety of non-steroidal anti-inflammatory drugs. DESIGN: Network meta-analysis. DATA SOURCES: Bibliographic databases, conference proceedings, study registers, the Food and Drug Administration website, reference lists of relevant articles, and reports citing relevant articles through the Science Citation Index (last update July 2009). Manufacturers of celecoxib and lumiracoxib provided additional data. STUDY SELECTION: All large scale randomised controlled trials comparing any non-steroidal anti-inflammatory drug with other non-steroidal anti-inflammatory drugs or placebo. Two investigators independently assessed eligibility. DATA EXTRACTION: The primary outcome was myocardial infarction. Secondary outcomes included stroke, death from cardiovascular disease, and death from any cause. Two investigators independently extracted data. DATA SYNTHESIS: 31 trials in 116 429 patients with more than 115 000 patient years of follow-up were included. Patients were allocated to naproxen, ibuprofen, diclofenac, celecoxib, etoricoxib, rofecoxib, lumiracoxib, or placebo. Compared with placebo, rofecoxib was associated with the highest risk of myocardial infarction (rate ratio 2.12, 95% credibility interval 1.26 to 3.56), followed by lumiracoxib (2.00, 0.71 to 6.21). Ibuprofen was associated with the highest risk of stroke (3.36, 1.00 to 11.6), followed by diclofenac (2.86, 1.09 to 8.36). Etoricoxib (4.07, 1.23 to 15.7) and diclofenac (3.98, 1.48 to 12.7) were associated with the highest risk of cardiovascular death. CONCLUSIONS: Although uncertainty remains, little evidence exists to suggest that any of the investigated drugs are safe in cardiovascular terms. Naproxen seemed least harmful. Cardiovascular risk needs to be taken into account when prescribing any non-steroidal anti-inflammatory drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Self-citationChen, X., Xiu, M., Xing, J., Yu, S., Min, D., & Guo, F. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479439 · Cited by 5,742
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Combination of direct and indirect evidence in mixed treatment comparisons
Lu, G., & Ades, A. E. (2004) · Statistics in Medicine · doi:10.1002/sim.1875 · Cited by 2,166
Statistics notes: Absence of evidence is not evidence of absence
Altman, D. G., & Bland, J. M. (1995) · BMJ · doi:10.1136/bmj.311.7003.485 · Cited by 1,946
Kaufman, D. W., Kelly, J. P., Rosenberg, L., Anderson, T. E., & Mitchell, A. A. (2002) · JAMA · doi:10.1001/jama.287.3.337 · Cited by 1,845
What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data
J. Sweeting, M., J. Sutton, A., & C. Lambert, P. (2004) · Statistics in Medicine · doi:10.1002/sim.1761 · Cited by 1,734
Simultaneous comparison of multiple treatments: Combining direct and indirect evidence.
Caldwell, D. M., Ades, A. E., & Higgins, J. P. T. (2005) · BMJ · doi:10.1136/bmj.331.7521.897 · Cited by 1,600
Kearney, P. M., Baigent, C., Godwin, J., Halls, H., Emberson, J. R., & Patrono, C. (2006) · BMJ · doi:10.1136/bmj.332.7553.1302 · Cited by 1,445
Egger, M., Jüni, P., Bartlett, C., Holenstein, F., & Sterne, J. (2003) · Health Technology Assessment · doi:10.3310/hta7010 · Cited by 1,181
Self-citationMcGettigan, P., & Henry, D. (2006) · JAMA · doi:10.1001/jama.296.13.jrv60011 · Cited by 1,096
Psaty, B. M., Lumley, T., Furberg, C. D., Schellenbaum, G., Pahor, M., Alderman, M. H., & Weiss, N. S. (2003) · JAMA · doi:10.1001/jama.289.19.2534 · Cited by 1,088
Grosser, T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27291 · Cited by 1,027
Coxibs and Cardiovascular Disease
FitzGerald, G. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048288 · Cited by 899
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Self-citationAssessing Evidence Inconsistency in Mixed Treatment Comparisons
Lu, G., & Ades, A. E. (2006) · Journal of the American Statistical Association · doi:10.1198/016214505000001302 · Cited by 756
Hippisley-Cox, J., & Coupland, C. (2005) · BMJ · doi:10.1136/bmj.330.7504.1366 · Cited by 561
BORROWING STRENGTH FROM EXTERNAL TRIALS IN A META-ANALYSIS
HIGGINS, J. P. T., & WHITEHEAD, A. (1996) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19961230)15:24<2733::aid-sim562>3.0.co;2-0 · Cited by 557
Cannon, C. P., Curtis, S. P., FitzGerald, G. A., Krum, H., Kaur, A., Bolognese, J. A., Reicin, A. S., Bombardier, C., Weinblatt, M. E., van der Heijde, D., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69666-9 · Cited by 522
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
Ray, W. A., Stein, C. M., Daugherty, J. R., Hall, K., Arbogast, P. G., & Griffin, M. R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11131-7 · Cited by 503
Solomon, S. D., Wittes, J., Finn, P. V., Fowler, R., Viner, J., Bertagnolli, M. M., Arber, N., Levin, B., Meinert, C. L., Martin, B., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.764530 · Cited by 367
Oral or transdermal opioids for osteoarthritis of the knee or hip
da Costa, B. R., Nüesch, E., Kasteler, R., Husni, E., Welch, V., Rutjes, A. W., & Jüni, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003115.pub4 · Cited by 347
Zhang, J., Ding, E. L., & Song, Y. (2006) · JAMA · doi:10.1001/jama.296.13.jrv60015 · Cited by 332
Zhang, W., Jones, A., & Doherty, M. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.018531 · Cited by 321
(2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.2.161 · Cited by 233
Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial
Baron, J. A., Sandler, R. S., Bresalier, R. S., Lanas, A., Morton, D. G., Riddell, R., Iverson, E. R., & DeMets, D. L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61490-7 · Cited by 232
Psaty, B. M., & Kronmal, R. A. (2008) · JAMA · doi:10.1001/jama.299.15.1813 · Cited by 173
Cooper, N. J., Sutton, A. J., Lu, G., & Khunti, K. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.12.1269 · Cited by 152
Shakespeare, T. P., Gebski, V., Veness, M., & Simes, J. R. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04522-0 · Cited by 138
Absence of evidence is not evidence of absence
Altman, D. G., & Bland, J. M. (1996) · Australian Veterinary Journal · doi:10.1111/j.1751-0813.1996.tb13786.x · Cited by 120
Hermann, M., Camici, G. G., Fratton, A., Hürlimann, D., Tanner, F. C., Hellermann, J. P., Fiedler, M., Thiery, J., Neidhart, M., Gay, R. E., et al. (2003) · Circulation · doi:10.1161/01.cir.0000101683.30157.0b · Cited by 118
Fries, J. F., Murtagh, K. N., Bennett, M. V., Zatarain, E., Lingala, B., & Bruce, B. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20440 · Cited by 117
National Trends in Cyclooxygenase-2 Inhibitor Use Since Market Release
Dai, C. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.2.171 · Cited by 110
Expression of Concern Reaffirmed
Curfman, G. D., Morrissey, S., & Drazen, J. M. (2006) · New England Journal of Medicine · doi:10.1056/nejme068054 · Cited by 109
Paulose‐Ram, R., Hirsch, R., Dillon, C. F., & Gu, Q. (2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.983 · Cited by 106
THIERS, B. H. (2007) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)70535-5 · Cited by 84
Cairns, J. A. (2007) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(07)70732-8 · Cited by 78
Wolfe, F., Flowers, N., Burke, T. A., Arguelles, L., & Pettitt, D. (2002) · PubMed · Cited by 73
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
Ray, W. A., Stein, C., Daugherty, J. R., Hall, K., Arbogast, P. G., & Griffin, M. R. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00991-1 · Cited by 64
van Staa, T. P., Leufkens, H. G. M., Zhang, B., & Smeeth, L. L. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000194 · Cited by 60
FDA Focuses on Drugs and Liver Damage
Kuehn, B. M. (2009) · JAMA · doi:10.1001/jama.2009.1019 · Cited by 48
EXTENT OF RENAL EFFECT OF CYCLO‐OXYGENASE‐2‐SELECTIVE INHIBITORS IS PHARMACOKINETIC DEPENDENT
Harirforoosh, S., Aghazadeh‐Habashi, A., & Jamali, F. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04464.x · Cited by 43
Chou, R., Fu, R. F., Carson, S., Saha, S. S., & Helfand, M. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.02.021 · Cited by 30
Keeping Science on Top in Drug Evaluation
Avorn, J. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078134 · Cited by 29
Gersh, B. J. (2009) · Yearbook of Medicine · doi:10.1016/s0084-3873(09)79449-0 · Cited by 21
THIERS, B. H. (2007) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)70536-7 · Cited by 21
Sowers, J. R., White, W. B., & Pitt, B. (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2005.03.009 · Cited by 20
Oral or transdermal opioids for osteoarthritis of the knee or hip
Nüesch, E., Rutjes, A., Husni, E., Welch, V., & Jüni, P. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003115.pub3 · Cited by 11
Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., et al. (2003) · JAMA · doi:10.1001/jama.289.21.2819 · Cited by 5
Cyclooxygenase Inhibition: What Should We Do to Resolve the Confusion? An American Perspective
BORER, J. S. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200605001-00016 · Cited by 2
Cited by
CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · JAMA · doi:10.1001/jama.2016.1464 · Cited by 5,161
OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis
Bannuru, R. R., Osani, M. C., Vaysbrot, E. E., Arden, N. K., Bennell, K., Bierma-Zeinstra, S. M. A., Kraus, V. B., Lohmander, L. S., Abbott, J. H., Bhandari, M., et al. (2019) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2019.06.011 · Cited by 3,542
CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6501e1 · Cited by 2,697
Salanti, G. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1037 · Cited by 1,729
Metadata
- Authors
- Trelle, S., Reichenbach, S., Wandel, S., Hildebrand, P., Tschannen, B., Villiger, P. M., Egger, M., & Juni, P.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2011-01-11
- Volume
- 342
- Issue
- jan11 1
- Pages
- c7086-c7086
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2010818945
- Cited by
- 1,166
- References
- 52
- FWCI
- 75.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.